August 28, 2003 |
Baxter International Inc., the world's largest maker of blood disease treatments, settled a lawsuit accusing Bayer Corp. and a former employee of stealing trade secrets about Baxter's products. Terms of the agreement weren't disclosed. Baxter had claimed that Gopal Dasari, a former Baxter Healthcare Corp. scientist who joined Bayer in May, had copied files on Baxter's products for hemophilia, cancer and kidney disease.
August 27, 2003 |
Baxter Healthcare Corp., a unit of the world's largest maker of blood disease treatments, is in settlement talks with Bayer Corp. to resolve an industrial espionage case. Attorneys for the companies told U.S. District Judge William Alsup in San Francisco that they were close to settling Baxter's suit, which alleges that Gopal Dasari, a former Baxter scientist who joined Bayer in May, copied files on Baxter's leading products for hemophilia, cancer and kidney disease.
May 22, 2003 |
A U.S. judge ruled that the 1997 agreement between Barr Laboratories Inc. and Bayer to end a patent suit over the anthrax treatment Cipro wasn't anti-competitive, according to Barr. U.S. District Judge David G. Trager in Brooklyn, N.Y., rejected arguments that the settlement violated antitrust laws. The ruling narrows the scope of some 38 antitrust lawsuits filed by consumers and wholesalers against Pomona, N.Y.-based Barr and Leverkusen, Germany-based Bayer.
October 26, 2001 |
Bayer has conspired to fix the price of anti-anthrax drug Cipro and acted to delay the production of generic versions, consumer advocacy groups claim in a lawsuit. Joining a suit filed last year in New York, the groups claim that Bayer and Barr Laboratories Inc. manipulated the prices of Cipro, which has been prescribed after a series of anthrax infections in New York, Washington, New Jersey and Florida that has claimed three lives. The original suit by Louisiana Wholesale Drug Co.
October 3, 2001 |
Bayer said Tuesday that it has agreed to buy Aventis CropScience for about $4.9 billion in cash to become the biggest maker of insecticides and help replace lost income from the withdrawn cholesterol treatment Baycol. The purchase from Aventis and Schering will yield annual savings of about 500 million euros with an elimination of 4,000 jobs, Bayer Chief Executive Manfred Schneider said at a news conference. The company also will assume $1.
August 15, 2001 |
The family of an Oklahoma man who died of kidney failure after taking cholesterol drug Baycol is suing the drug's U.S. manufacturer, Bayer Corp., a family attorney said Tuesday. It was the first announcement of a U.S. suit linking Baycol with deceased patients who took the drug and the first suit in which class-action status is being sought, said the lawyer, Don Strong of Strong, Martin & Associates. Bayer Corp.'